Sarepta shares surge after surprise approval of DMD drug
By Tamara Mathias (Reuters) – Shares of Sarepta Therapeutics Inc soared 32% on Friday after U.S. regulators shocked Wall Street by reversing their rejection of its muscle-wasting disorder therapy less than four months ago,...
Read More